Troponin I phosphorylation in human myocardium in health and disease

P. J M Wijnker, Anne M Murphy, G. J M Stienen, J. van der Velden

Research output: Contribution to journalArticle

Abstract

Cardiac troponin I (cTnI) is well known as a biomarker for the diagnosis of myocardial damage. However, because of its central role in the regulation of contraction and relaxation in heart muscle, cTnI may also be a potential target for the treatment of heart failure. Studies in rodent models of cardiac disease and human heart samples showed altered phosphorylation at various sites on cTnI (i.e. site-specific phosphorylation). This is caused by altered expression and/or activity of kinases and phosphatases during heart failure development. It is not known whether these (transient) alterations in cTnI phosphorylation are beneficial or detrimental. Knowledge of the effects of site-specific cTnI phosphorylation on cardiomyocyte contractility is therefore of utmost importance for the development of new therapeutic strategies in patients with heart failure. In this review we focus on the role of cTnI phosphorylation in the healthy heart upon activation of the beta-adrenergic receptor pathway (as occurs during increased stress and exercise) and as a modulator of the Frank-Starling mechanism. Moreover, we provide an overview of recent studies which aimed to reveal the functional consequences of changes in cTnI phosphorylation in cardiac disease.

Original languageEnglish (US)
Pages (from-to)463-469
Number of pages7
JournalNetherlands Heart Journal
Volume22
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Troponin I
Myocardium
Phosphorylation
Health
Heart Failure
Heart Diseases
Starlings
Receptors, Adrenergic, beta
Treatment Failure
Phosphoric Monoester Hydrolases
Cardiac Myocytes
Rodentia
Phosphotransferases
Biomarkers
Exercise

Keywords

  • Cardiac troponin I
  • Heart failure
  • Myofilament function
  • Phosphorylation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Troponin I phosphorylation in human myocardium in health and disease. / Wijnker, P. J M; Murphy, Anne M; Stienen, G. J M; van der Velden, J.

In: Netherlands Heart Journal, Vol. 22, No. 10, 01.10.2014, p. 463-469.

Research output: Contribution to journalArticle

Wijnker, P. J M ; Murphy, Anne M ; Stienen, G. J M ; van der Velden, J. / Troponin I phosphorylation in human myocardium in health and disease. In: Netherlands Heart Journal. 2014 ; Vol. 22, No. 10. pp. 463-469.
@article{6467d6c6599c4f52b3c0d838fb85a78b,
title = "Troponin I phosphorylation in human myocardium in health and disease",
abstract = "Cardiac troponin I (cTnI) is well known as a biomarker for the diagnosis of myocardial damage. However, because of its central role in the regulation of contraction and relaxation in heart muscle, cTnI may also be a potential target for the treatment of heart failure. Studies in rodent models of cardiac disease and human heart samples showed altered phosphorylation at various sites on cTnI (i.e. site-specific phosphorylation). This is caused by altered expression and/or activity of kinases and phosphatases during heart failure development. It is not known whether these (transient) alterations in cTnI phosphorylation are beneficial or detrimental. Knowledge of the effects of site-specific cTnI phosphorylation on cardiomyocyte contractility is therefore of utmost importance for the development of new therapeutic strategies in patients with heart failure. In this review we focus on the role of cTnI phosphorylation in the healthy heart upon activation of the beta-adrenergic receptor pathway (as occurs during increased stress and exercise) and as a modulator of the Frank-Starling mechanism. Moreover, we provide an overview of recent studies which aimed to reveal the functional consequences of changes in cTnI phosphorylation in cardiac disease.",
keywords = "Cardiac troponin I, Heart failure, Myofilament function, Phosphorylation",
author = "Wijnker, {P. J M} and Murphy, {Anne M} and Stienen, {G. J M} and {van der Velden}, J.",
year = "2014",
month = "10",
day = "1",
doi = "10.1007/s12471-014-0590-4",
language = "English (US)",
volume = "22",
pages = "463--469",
journal = "Netherlands Heart Journal",
issn = "1568-5888",
publisher = "Bohn Stafleu van Loghum",
number = "10",

}

TY - JOUR

T1 - Troponin I phosphorylation in human myocardium in health and disease

AU - Wijnker, P. J M

AU - Murphy, Anne M

AU - Stienen, G. J M

AU - van der Velden, J.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Cardiac troponin I (cTnI) is well known as a biomarker for the diagnosis of myocardial damage. However, because of its central role in the regulation of contraction and relaxation in heart muscle, cTnI may also be a potential target for the treatment of heart failure. Studies in rodent models of cardiac disease and human heart samples showed altered phosphorylation at various sites on cTnI (i.e. site-specific phosphorylation). This is caused by altered expression and/or activity of kinases and phosphatases during heart failure development. It is not known whether these (transient) alterations in cTnI phosphorylation are beneficial or detrimental. Knowledge of the effects of site-specific cTnI phosphorylation on cardiomyocyte contractility is therefore of utmost importance for the development of new therapeutic strategies in patients with heart failure. In this review we focus on the role of cTnI phosphorylation in the healthy heart upon activation of the beta-adrenergic receptor pathway (as occurs during increased stress and exercise) and as a modulator of the Frank-Starling mechanism. Moreover, we provide an overview of recent studies which aimed to reveal the functional consequences of changes in cTnI phosphorylation in cardiac disease.

AB - Cardiac troponin I (cTnI) is well known as a biomarker for the diagnosis of myocardial damage. However, because of its central role in the regulation of contraction and relaxation in heart muscle, cTnI may also be a potential target for the treatment of heart failure. Studies in rodent models of cardiac disease and human heart samples showed altered phosphorylation at various sites on cTnI (i.e. site-specific phosphorylation). This is caused by altered expression and/or activity of kinases and phosphatases during heart failure development. It is not known whether these (transient) alterations in cTnI phosphorylation are beneficial or detrimental. Knowledge of the effects of site-specific cTnI phosphorylation on cardiomyocyte contractility is therefore of utmost importance for the development of new therapeutic strategies in patients with heart failure. In this review we focus on the role of cTnI phosphorylation in the healthy heart upon activation of the beta-adrenergic receptor pathway (as occurs during increased stress and exercise) and as a modulator of the Frank-Starling mechanism. Moreover, we provide an overview of recent studies which aimed to reveal the functional consequences of changes in cTnI phosphorylation in cardiac disease.

KW - Cardiac troponin I

KW - Heart failure

KW - Myofilament function

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=84908040879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908040879&partnerID=8YFLogxK

U2 - 10.1007/s12471-014-0590-4

DO - 10.1007/s12471-014-0590-4

M3 - Article

C2 - 25200323

AN - SCOPUS:84908040879

VL - 22

SP - 463

EP - 469

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

SN - 1568-5888

IS - 10

ER -